Improving the clinical trial landscape for Parkinson syndromes in Germany
Journal of Neural Transmission · 2026-10 · 133 (10) · 3023-3032
DOI: 10.1007/s00702-026-03314-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neural Transmission, online erschienen am 24.10.2026. Verfasst von Günter Höglinger und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, LMU University Hospital, Ludwig-Maximilians- Universität (LMU) München, Munich, Germany. Guenter.Hoeglinger@med.uni-muenchen…. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Parkinson Disease. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Germany has a longstanding tradition of excellence in neuroscience and Parkinson’s research, supported by outstanding academic institutions, specialized clinical centers, and a strong scientific community. Building on this strong foundation, the country now has the opportunity to transform its clinical research landscape into a more integrated ecosystem for Parkinson syndromes. Despite major advances in molecular understanding, biomarker development, and therapeutic innovation, important structural, regulatory, financial, and organizational barriers continue to limit the full translational potential of German Parkinson research. Participants in an expert workshop identified identify recurring challenges, including fragmented trial infrastructures, slow and bureaucratic regulatory procedures, insufficient funding for investigator-initiated clinical research, limited integration of patient organizations, and suboptimal patient recruitment pathways. This workshop-derived perspective outlines a strategic framework to elevate Germany from a country with excellent individual centers to a globally competitive and integrated hub for innovative Parkinson clinical research. Key recommendations include transforming the German Parkinson Study Group into a nationally coordinated, service-oriented trial network; establishing centralized digital and regulatory infrastructures; diversifying public and philanthropic funding; implementing platform and observational trial structures; strengthening incentives for participating centers; and enhancing patient engagement through national registries, decentralized trial approaches, real-world data based evidence surveillance, and systematic integration of patient organizations. The authors argue that Germany must move beyond isolated university-based structures toward a nationally coordinated and highly efficient research ecosystem capable of rapidly delivering disease-modifying and precision medicine trials. Such a transformation could strengthen Germany’s international position in neurodegenerative disease research and accelerate therapeutic innovation for patients with Parkinson syndromes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, LMU University Hospital, Ludwig-Maximilians- Universität (LMU) München, Munich, Germany. Guenter.Hoeglinger@med.uni-muenchen.de.
- German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. Guenter.Hoeglinger@med.uni-muenchen.de.
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. Guenter.Hoeglinger@med.uni-muenchen.de.
- Department of Neurology, LMU University Hospital, Ludwig-Maximilians- University (LMU) Munich, Marchioninistr. 15, 81377, Munich, Germany. Guenter.Hoeglinger@med.uni-muenchen.de.
- Department of Neurology, University Hospital Marburg, Marburg, Germany.
- Dept. of Neurology, University Hospital Leipzig, Leipzig, Germany.
ORCID-Profile: Günter Höglinger
Zitieren
APA
Höglinger, G., Eggert, K., Classen, J., van Eimeren, T., Höllerhage, M., Jost, W. H., Kassubek, J., Klucken, J., Koeglsperger, T., Krüger, R., Müller, T., Pötter-Nerger, M., Riederer, P., Storch, A., Winkler, J., Wüllner, U., Schindler, C., Lingor, P., & German Parkinson’s Experts Meeting Group (2026). Improving the clinical trial landscape for Parkinson syndromes in Germany. Journal of Neural Transmission, 133(10), 3023-3032. https://doi.org/10.1007/s00702-026-03314-w
Vancouver
Höglinger G, Eggert K, Classen J, van Eimeren T, Höllerhage M, Jost WH, et al. Improving the clinical trial landscape for Parkinson syndromes in Germany. Journal of Neural Transmission. 2026;133(10):3023-3032. doi:10.1007/s00702-026-03314-w
BibTeX
@article{Hglinger2026,
author = {Höglinger, Günter and Eggert, Karla and Classen, Joseph and van Eimeren, Thilo and Höllerhage, Matthias and Jost, Wolfgang H and Kassubek, Jan and Klucken, Jochen and Koeglsperger, Thomas and Krüger, Rejko and Müller, Thomas and Pötter-Nerger, Monika and Riederer, Peter and Storch, Alexander and Winkler, Jürgen and Wüllner, Ullrich and Schindler, Christoph and Lingor, Paul and German Parkinson’s Experts Meeting Group, German Parkinson’s Experts Meeting Group},
title = {Improving the clinical trial landscape for Parkinson syndromes in Germany},
journal = {Journal of Neural Transmission},
year = {2026},
volume = {133},
number = {10},
pages = {3023--3032},
doi = {10.1007/s00702-026-03314-w}
}
EUVIMED